Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway

Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel. However, synergy may not be fully exploited clinically because of distinct pharmacokin...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Blanco, Elvin, Sangai, Takafumi, Wu, Suhong, Hsiao, Angela, Ruiz-Esparza, Guillermo U, Gonzalez-Delgado, Carlos A, Cara, Francisca E, Granados-Principal, Sergio, Evans, Kurt W, Akcakanat, Argun, Wang, Ying, Do, Kim-Anh, Meric-Bernstam, Funda, Ferrari, Mauro
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2014
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4088997/
https://ncbi.nlm.nih.gov/pubmed/24569835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2014.27
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky